FJ Bioscience(馥逸医疗), a surgical robot startup based in Shanghai, has announced the completion of a Series A round of funding for an undisclosed amount of money, PE Daily, a VC-focused media outlet reported today.
The round was led by Sequoia China, with participation from existing shareholder Dalton Venture.
Proceeds from this fundraiser will be used to accelerate the development of its product pipeline, clinical trial, talent recruitment, construction of a R&D center and use of a Good Manufacturing Practices (GMP) workshop.
Founded in September 2021, the startup focuses on manufacturing robots to assist microsurgery on human neck and head.
Based on a bionic, dual-arm robotic platform, the company is dedicated to building a product matrix comprising smart, high-precision and bionic surgical robots.
FJ Bioscience says its core founding members have rich experience in medical equipment engineering and surgical robot development.
The firm says it has external advisors who are leading academicians on surgical robotics, clinical experts at top-tier hospitals and investors at renowned medtech-focused venture funds.
As a result of this mix of talent, the firm believes it has acquired rich experience in areas from knowing patient demand at the clinical stage and biomedical engineering, to development of surgical robots and clinical trial registration.
However, FJ Bioscience did not disclose any further information on which medical institutions are using its technologies and how many surgeries have been completed with its robots.
